Current treatment status-Undergoing active treatment-Progressive despite several lines of treatment Posts on Medivizor
Navigation Menu

Current treatment status-Undergoing active treatment-Progressive despite several lines of treatment Posts on Medivizor

Evaluating brentuximab vedotin plus bendamustine for patients with hard-to-treat classical Hodgkin lymphoma

Posted by on Mar 8, 2020 in Hodgkin's lymphoma | 0 comments

In a nutshell This study evaluated the effectiveness of brentuximab vedotin (Adcetris) plus bendamustine (Treanda) for patients with hard to treat classical Hodgkin lymphoma (cHL). This study found that this regimen is an effective salvage therapy for these patients. Some background Standard first-line chemotherapy is highly effective in treating...

Read More

The comparison of outcomes of two salvage therapies in patients with relapsed or unresponsive acute myeloid leukemia

Posted by on Mar 4, 2020 in Leukemia | 0 comments

In a nutshell The study evaluated the effectiveness of two salvage therapies – mitoxantrone (Novantrone), etoposide (Etopophos), and cytarabine (Cytosar-U) also known as MEC and cladribine (Leustatin), cytarabine, filgrastim (Neupogen), and mitoxantrone also known as CLAG-M, for treating relapsed/refractory acute myeloid leukemia...

Read More

Venetoclax in elderly patients with relapsed or unresponsive chronic lymphocytic leukemia

Posted by on Feb 25, 2020 in Leukemia | 0 comments

In a nutshell This study aimed to investigate if venetoclax was safe and effective in older patients with relapsed/refractory chronic lymphocytic leukemia outside of clinical trials. This study concluded that venetoclax is safe and effective in these patients. Some background Chronic lymphocytic leukemia (CLL) is commonly diagnosed in older people....

Read More

Evaluating stem cell transplant outcomes for patients classical Hodgkin’s lymphoma

Posted by on Feb 16, 2020 in Hodgkin's lymphoma | 0 comments

In a nutshell This study looked at the outcomes of autologous stem cell transplantation (ASCT) to treat recurrent classical Hodgkin’s lymphoma (cHL). This study concluded that ASCT is effective, with patients who responded after the transplant having the best outcomes. Some background cHL is usually treated with chemotherapy and...

Read More

Evaluating BEGEV chemotherapy before a stem cell transplant for hard-to-treat Hodgkin lymphoma

Posted by on Feb 5, 2020 in Hodgkin's lymphoma | 0 comments

In a nutshell This study evaluated the effectiveness of BEGEV chemotherapy for patients with relapsed or unresponsive Hodgkin lymphoma (HL) before a stem cell transplant. The authors concluded that this regimen was safe and effective for these patients. Some background Chemotherapy, followed by a stem cell transplant (SCT), remains the standard of...

Read More

How effective is long-term brentuximab vedotin treatment for patients with recurrent or non-responding Hodgkin’s lymphoma?

Posted by on Jan 12, 2020 in Hodgkin's lymphoma | 0 comments

In a nutshell This study evaluated long-term treatment with brentuximab vedotin (Adcetris) for patients with Hodgkin's lymphoma (HL) that has come back or stopped responding to treatment. This study concluded that this treatment had a long-term benefit for some patients. Some background Most patients with HL respond well to initial treatment....

Read More

Evaluating isatuximab for patients with recurrent or non-responding multiple myeloma

Posted by on Jan 8, 2020 in Multiple Myeloma | 0 comments

In a nutshell This study examined the effectiveness and safety of isatuximab plus PD (pomalidomide, dexamethasone) for patients with multiple myeloma (MM) that has come back or stopped responding to treatment. This study concluded that isatuximab was well-tolerated and significantly improved survival outcomes for these patients. Some...

Read More

Minimal residual disease status after inotuzumab ozogamicin in patients with relapsed/refractory acute lymphoblastic leukemia

Posted by on Jan 7, 2020 in Leukemia | 0 comments

In a nutshell This study aimed to investigate if minimal residual disease negativity is useful as a prognostic factor after inotuzumab ozogamicin treatment in patients with relapsed/refractory acute lymphoblastic leukemia.   This study concluded minimal residual negativity with complete remission is associated with a better...

Read More

Evaluating gemcitabine plus bendamustine for patients with non-responsive Hodgkin lymphoma

Posted by on Dec 28, 2019 in Hodgkin's lymphoma | 0 comments

In a nutshell This study evaluated the safety and effectiveness of gemcitabine (Gemzar) plus bendamustine (Treanda) in patients with Hodgkin lymphoma (HL) that has come back or stopped responding to treatment. This study found that this combination was well-tolerated and effective for these patients. Some background Immunotherapy remains a...

Read More

Managing advanced phase chronic myeloid leukemia

Posted by on Dec 24, 2019 in Leukemia | 0 comments

In a nutshell This study reviewed treatment options for advanced phase chronic myeloid leukemia. This study concluded that managing advanced phase chronic myeloid leukemia remains challenging and treatment options include tyrosine kinase inhibitors, chemotherapy, and transplant.  Some background Chronic myeloid leukemia (CML) can be...

Read More